Glenmark Pharma gets nod for combination of Remogliflozin and Metformin

19 Aug 2019 Evaluate

Glenmark Pharmaceuticals has received regulatory approval to market a combination of its novel, patent protected and globally?researched sodium glucose co?transporter?2 (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) and Metformin Hydrochloride (Metformin) film coated tablets in India.

The drug is indicated in the treatment of type?2 diabetes mellitus in adults. The company will commercialize the product under the brand names ‘Remo?M’ and Remozen?M’

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×